Displaying 1 - 1 of 1
| Active Ingredient | MEFLOQUINE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Mefloquine is indicated for the prophylaxis and the treatment of mild to moderate malaria caused by Plasmodium vivax and susceptible strains of Plasmodium falciparum. |
| Caution | Anorexia, vomiting, nausea, diarrhoea, dizziness ,sleep disturbance, panic attacks, sudden on set of anxiety , restlessness, irritability, confusion, persistently abnormal heart beat, palpitations, b More ... |
| Dose Range | Acute disease: 5 tablets (1250mg) should be given as a single oral dose or 750mg initially followed by 500mg given 12 hours later. Prophylaxis: 250mg per week prior to departure (commence 1-3weeks prior to travel), during period in endemic area and 4 weeks after return. Alternatively : 250mg for 3 days followed by 250mg weekly (in cases where a loading dose is required). (NB: 250mg M efloquine HCL = 228mg of the base). |
| Drug Interactions | When mefloquine is used for prevention or chemoprophylaxis of malaria in travelers, possible effects of mefloquine on other drugs these individuals are receiving (especially anticoagulants and antidia More ... |
| Pregnancy | Manufacturer advises avoid unless the potential benefit outweighs the risk parti More ... |
| Breast Feeding | Present in milk but risk to infant minimal. |